FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia... Show more
FGEN is expected to report earnings to fall 155.56% to -10 cents per share on May 12
Q1'25
Est.
$-0.10
Q4'24
Beat
by $0.35
Q3'24
Beat
by $0.14
Q2'24
Beat
by $0.16
Q1'24
Beat
by $0.08
The last earnings report on March 17 showed earnings per share of 18 cents, beating the estimate of -17 cents. With 613.37K shares outstanding, the current market capitalization sits at 30.90M.